Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib

Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients. However, a significant portion of MM patients do not respond to PI therapies. Drug resistan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Chem
Main Authors: Lee, Min Jae, Bhattarai, Deepak, Yoo, Jisu, Miller, Zach, Park, Ji Eun, Lee, Sukyeong, Lee, Wooin, Driscoll, James J., Kim, Kyung Bo
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7675178/
https://ncbi.nlm.nih.gov/pubmed/30964987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b01943
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados